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Abstract
Human topoisomerase I (Top1) relaxes supercoiled DNA during cell division. Camptothecin stabilizes Top1/dsDNA covalent
complexes which ultimately results in cell death, and this makes Top1 an anti-cancer target. There are two current models
for how camptothecin and derivatives bind to Top1/dsDNA covalent complexes (Staker, et al., 2002, Proc Natl Acad Sci USA
99: 15387–15392; and Laco, et al., 2004, Bioorg Med Chem 12: 5225–5235). The interaction energies between bound
camptothecin, and derivatives, and Top1/dsDNA in the two models were calculated. The published structure-activity-
relationships for camptothecin and derivatives correlated with the interaction energies for camptothecin and derivatives in
the Laco et al. model, however, this was not the case for several camptothecin derivatives in the Stacker et al. model. By
defining the binding orientation of camptothecin and derivatives in the Top1/dsDNA active-site these results allow for the
rational design of potentially more efficacious camptothecin derivatives.
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Introduction
Camptothecin (CPT) is a natural product that was isolated from
the Chinese tree Camptotheca acuminata by Wall and Wani and was
shown to inhibit the growth of cancer cells in cell culture [1].
Derivatives of CPT, including topotecan and irinotecan, have
been approved by the Food and Drug Administration for the
treatment of cancer. Several groups have shown that CPT
specifically targets human topoisomerase type IB (Top1) [2,3].
Top1 binds dsDNA and attacks the backbone scissile bond
phosphate with the active-site Tyr723 to make a covalent tyrosyl-
phosphate bond to the -1 scissile strand deoxyribonucleotide (-1
nucleotide). This results in a +1 deoxyribonucleoside (+1
nucleoside) with a free 59-OH. CPT stabilizes the Top1/dsDNA
covalent complex [4]. When cells replicate DNA containing CPT
stabilized Top1/dsDNA covalent complexes the single-strand
breaks are converted into dsDNA breaks and it is thought that this
ultimately results in cell death [5–7]. Numerous derivatives of
CPT have been designed and synthesized to increase specificity
and bioavailability, reviewed in [8,9]. However, one problem
associated with the use of CPT derivatives in the treatment of
breast cancer is the development of drug resistance [9]. Breast
cancer resistance has been linked to the over expression of the
breast cancer resistance protein, the substrates for which are
planar with conjugated pi-orbitals and with an OH or amino
group at the A-ring 10 position of CPT derivatives [10]. A model
of CPT binding in the Top1/dsDNA active-site would allow for
the rational design of CPT derivatives which are not substrates for
the breast cancer resistance protein.
A key result in the Top1 field was obtained when Redinbo et al.
solved the X-ray crystal structure of Top1 in covalent complex
with a suicide-DNA [11]. Since Top1 has a low affinity for relaxed
dsDNA, a suicide dsDNA oligonucleotide (suicide-DNA) was used
to generate the Top1/suicide-DNA covalent complexes [11]. The
suicide-DNA differed from native dsDNA in that the backbone
scissile bond 59 oxygen (O59) was replaced with a sulfur. When the
Top1 active-site Tyr723 attacked the suicide-DNA it generated a
native tyrosyl-phosphate bond to the 39 end of the -1 nucleotide
while leaving a non-native 59-SH on the free end of the +1
nucleoside [11,12]. And while the 59-SH can attack the tyrosyl-
phosphate bond resulting in religation of the scissile strand DNA
backbone, the equilibrium is shifted ,7-fold towards the Top1/
dsDNA covalent complex [13]. As a result, Top1 remained
trapped in covalent complex with the suicide-DNA in the crystals
[11]. The Redinbo et al. structure allowed for the structure-based
modeling of CPT and derivatives in the Top1/suicide-DNA active
site and resulted in models by Redinbo et al. [11], Kerrigan et al.
[14], and Laco et al. [15], the last of which is described here as the
Rotated +1 Nucleoside model.
Of these structure-based Top1/dsDNA/inhibitor models, only
the orientation of CPT and derivatives in the Rotated +1
Nucleoside model were experimentally tested in vitro using both
a Top1 Asn352Ala mutant and a dsDNA oligonucleotide assay
which used cobalt to oxidize extra helical guanines [15,16]. In the
Laco et al. Rotated +1 Nucleoside model, the +1 nucleoside
rotated out of the helix when Top1 was in covalent complex with
supercoiled dsDNA. As a result of the rotation, the free 59OH of
the +1 nucleoside was out of range (7.7 A ˚) of the tyrosyl-phosphate
bond preventing religation of the DNA backbone [15]. This
finding supports the processive nature of Top1 in that it stays
bound to supercoiled dsDNA until the dsDNA is fully relaxed [17].
After the dsDNA is fully relaxed, the +1 nucleoside is rotated back
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tyrosyl-phosphate bond, religate the DNA backbone, and allow
Top1 to dissociate from the fully relaxed dsDNA [15]. Rotation of
the +1 nucleoside out of the helix leaves a cavity in the Top1/
dsDNA active-site which can be occupied by CPT and derivatives.
When CPT and derivatives bind in the Rotated +1 Nucleoside
model Top1/dsDNA active-site they block the +1 nucleoside from
re-entering the helix thus stabilizing the Top1/dsDNA covalent
complex [15].
The Rotated +1 Nucleoside model is significantly different from
the Staker et al. X-ray crystallography based models of Top1 in
covalent complex with suicide-DNA and either topotecan [18] or
CPT [19]. In both Staker et al. structure based models the +1
nucleoside was based-paired in the helix, and the inhibitors
intercalated in between the -1 and +1 base pairs, forcing the +1
base pairs ,3.4 A ˚ further away from the -1 base pairs [18,19]. As
a result, the suicide-DNA +1 nucleoside 59SH was 11.6 A ˚ away
from the tyrosyl-phosphate bond preventing religation of the DNA
[18,19]. The Staker et al. structure-based model of Top1 in
covalent complex with dsDNA and bound inhibitor is described
here as the ‘‘Intercalated model’’. The Rotated +1 Nucleoside
model and the Intercalated model were evaluated in silico using
Discovery Studio computational chemistry software (Accelrys, San
Diego, CA). This approach allowed for evaluation of the binding
orientations of CPT and derivatives in the Rotated +1 Nucleoside
and Intercalated models, to see which binding orientation
correlated best with the reported in vitro structure-activity-
relationships for CPT and derivatives.
Results and Discussion
CPT and derivatives selected for this study, along with the
respective in vitro inhibition results for each, are shown in Figure 1
and Table 1 [15,16,20]. There were three selection criteria for the
inhibitors used in this study: 1) inhibitors had been tested in an in
vitro Top1 dsDNA oligonucleotide assay in which the dsDNA
oligonucleotide had a single high affinity Top1 cleavage site; 2) the
assay measured the accumulation of Top1/dsDNA covalent
complexes over time; and 3) inhibitors were tested at three or
more concentrations to quantitate inhibition. As a result,
topotecan was not included in the study due to the lack of
published reports documenting the in vitro inhibition activity of
topotecan using the same assay and conditions as for the inhibitors
in Table 1 [21,22]. The original Laco et al. model of Top1 in
covalent complex with DNA and inhibitor [15] was based on the
Redinbo et al. X-ray crystal structure of Top1 in covalent complex
with suicide-DNA [11]. A reconstituted Top1 was used to generate
the Redinbo et al. Top1/suicide-DNA covalent-complex structure
and the following Top1 residues were not resolved in the
functional domain which includes the DNA binding and
enzymatic domains of Top1 (aa 201–265) [17]: residues 201–
214; core residues 627–634, linker residues 635–697; and C-
terminal residues 698–719 which are part of the Top1 active-site
[11]. A more recent structure by Staker et al. of a Top1/suicide-
DNA/topotecan ternary complex resolved all main-chain Top1
atoms in the functional domain [18]. However, in that structure
the intercalated topotecan, a CPT derivative with an A-ring 9-
CH2N(CH3)2 and 10-OH, displaced the +1 bases ,3.4 A ˚ further
away from the cleavage-site -1 base pairs. In order to generate a
structurally complete model of Top1 in covalent-complex with
native dsDNA and no inhibitor the displaced DNA strands were
replaced in the Stacker et al. Top1/suicide-DNA/topotecan
structure [18] with the corresponding DNA strands from the
Redinbo et al. Top1/suicide DNA structure [11] using Discovery
Studio and the Consistent Force Field (CFF) which has parameters
for protein, DNA, and small ligands (Methods). Next, the +1
nucleoside was rotated out of the helix until it was trapped in a
network of H-bonds/electrostatic interactions with Arg488,
Asp533, Arg590 as previously reported [15]. CPT was then
docked into the active-site of the Rotated +1 Nucleoside model
and modified into the indicated CPT derivatives (Figure 1 and
Table 1); with 10-OH CPT shown in the Rotated +1 Nucleoside
model active-site in Figure 2. The orientations of CPT and
derivatives in this structurally complete Rotated +1 Nucleoside
model were similar to the Laco et al. model [15] that was based on
the incomplete Top1/suicide-DNA structure by Redinbo et al.
[11]. In addition, the suicide-DNA backbone sulfur, that is found
as a free 59SH on the +1 nucleoside, was changed to the native
oxygen [11,18,19]. Explicit waters were added to the Rotated +1
Nucleoside model presented here followed by minimization,
however, individual waters did not make any bridging H-bonds/
electrostatic interactions between 10-OH CPT and the Top1/
dsDNA active-site (data not shown). This result is consistent with
previously published results on the Rotated +1 Nucleoside model
in which individual explicit waters did not make bridging H-bond
interactions between ligands and the Top1/dsDNA active-site
[15]. As a result, all Rotated +1 Nucleoside model Top1/dsDNA/
inhibitor complexes were minimized with an implicit solvent
model (Methods).
The Staker et al. structure based Intercalated model of Top1 in
covalent complex with suicide-DNA and topotecan was modified
Figure 1. Structure of CPT and hCPT E-ring. CPT left, hCPT E-ring
right; hCPT and derivatives differ from CPT in that they contain an
additional E-ring carbon between the 20-OH and the adjacent carbonyl
oxygen to give a seven-member E-ring.
doi:10.1371/journal.pone.0024314.g001




CPT H H OH 0.9*
hCPT H H OH 1.0*
6 20-deoxy CPT H H H 0.03**
6 20-Cl CPT H H Cl 0.29**
10-OH CPT OH H OH 3.5*
10,11-diF hCPT FF OH 12.0*
Modified A-ring ring positions (10, 11) and E-ring position (20) are indicated for
CPT/hCPT derivatives; modifications shown in italics (see Fig. 1 for CPT and
hCPT structures).
*As reported by Laco et al. [15,16].
**As reported by Wang et al. for racemic CPT derivatives [20]. All Top1 inhibition
assays were performed using an end-labeled dsDNA oligonucleotide.
doi:10.1371/journal.pone.0024314.t001
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10-OH CPT, and the suicide-DNA backbone sulfur was changed
to the native oxygen (Fig. 1 and 3, Table 1, Methods). In the
Staker et al. structure of topotecan in ternary complex with Top1
and suicide-DNA two crystallographic waters were found to make
bridging H-bonds between the topotecan carboxylate and Top1
active-site residues [18], however, carboxylate forms of CPT
derivatives have been shown to be inactive [15]. One additional
water was found to be within 2.9 A ˚ of the topotecan A-ring 10-
OH, but there were no Top1/dsDNA H-bond donor/acceptor
residues within 4.4 A ˚ of that water [18]. Here the Intercalated
model was initially solvated with explicit waters followed by
minimization, and a water was found close to the 10-OH of 10-
OH CPT, however, the only other H-bond donors/acceptors
within 4.4 A ˚ were other waters (data not shown). Since no
individual waters were found to make bridging H-bond/
electrostatic interactions between the inhibitor and the Top1/
dsDNA active-site, all Intercalated model Top1/dsDNA/inhibitor
complexes were minimized with an implicit solvent model
(Methods). 10-OH CPT is shown in the Intercalated model
Top1/dsDNA active-site in Figure 3. The Top1/suicide-DNA/
topotecan X-ray crystallography based model was used here
because Top1 in the Top1/suicide-DNA/CPT model was not
structurally complete [19].
The inclusion of explicit water molecules during an interaction
energy calculation between an inhibitor and Top1/dsDNA would
artificially make the electrostatic component of the interaction
energy score more negative (i.e., stronger) when individual waters
Figure 2. Rotated +1 Nucleoside model for Top1 interaction
with dsDNA and 10-OH CPT. A) Rotated +1 Nucleoside model, Top1
shown as blue ribbon, dsDNA in teal with the rotated +1 deoxygua-
nosine left of 10-OH CPT (CPK rendering; carbon, green; oxygen, red;
nitrogen, blue; hydrogen, white). B) Rotated +1 Nucleoside model, close
up of Fig. 2A active-site. 10-OH CPT with E-ring in foreground, bound in
the Top1/dsDNA active-site in which the +1 scissile strand G is rotated
out of the helix to the left until trapped in a network of H-bonds/
electrostatic interactions with Asp533 (center) and Arg488/Arg590 (not
shown for clarity, see Fig. 4A). Selected atoms involved in H-bonds/
electrostatic interactions are colored: nitrogen, blue; oxygen, red;
hydrogen, white. Top1 side-chain carbons are yellow, except for Tyr723
(red) in tyrosyl-phosphate bond (phosphorus, orange) to the -1 scissile
strand T. 10-OH CPT interactions: 10-OH CPT D-ring stacks over the -1
scissile strand T; 20-OH H-bonds to -1 scissile strand T carbonyl oxygen;
A-ring 10-OH oxygen makes electrostatic interaction with Asn352
nitrogen (3.6 A ˚); E-ring carbonyl oxygen H-bonds to Lys532 nitrogen; C-
ring carbonyl oxygen H-bonds to Asn722 nitrogen. Scissile strand
rotated +1G5 9OH H-bonds to Asp533. Arg364 nitrogens H-bond to +1
non-scissile strand C carbonyl oxygen and -1 non-scissile strand A
nitrogen. Scissile strand, ss; non-scissile strand, ns. For flat image see
Fig. 4A.
doi:10.1371/journal.pone.0024314.g002
Figure 3. Intercalated model for Top1 interaction with dsDNA
and 10-OH CPT. A) Intercalated model; Top1 shown as blue ribbon,
dsDNA in teal, 10-OH CPT center (CPK rendering; carbon, bronze;
oxygen, red; nitrogen, blue; hydrogen, white). B) Intercalated model,
close up of Fig. 3A active-site. 10-OH CPT (carbons bronze) with E-ring
in foreground intercalated between the -1 and +1 base pairs in the
Top1/dsDNA active-site. 10-OH CPT interactions: 10-OH CPT stacks in
between the +1 and -1 base pairs; A-ring 10-OH H-bonds to Glu356
oxygen; E-ring 20-OH H-bonds to Asp533 oxygen; D-ring carbonyl
oxygen makes an electrostatic interaction with Asn722 (4.1 A ˚). Arg364
H-bonds with the -1 non-scissile strand T, Lys 532 H-bonds to the -1
scissile strand T carbonyl oxygen. Top1 active-site Tyr723 (red, left) is
shown making a tyrosyl-phosphate bond to the -1 scissile strand T.
Scissile strand, ss; non-scissile strand, ns. For flat image see Fig. 4B.
doi:10.1371/journal.pone.0024314.g003
Evaluation of Human Topoisomerase I Inhibition
PLoS ONE | www.plosone.org 3 August 2011 | Volume 6 | Issue 8 | e24314do not mediate significant bridging H-bonds/electrostatic inter-
actions between the inhibitor and the Top1/dsDNA active-site.
Similarities and differences between Rotated +1
Nucleoside and Intercalated Models
While the orientation of 10-OH CPT and DNA in the two
models is overall strikingly different, there are similarities and they
are described first. Top1 active-site residues Arg364, Lys532, and
Arg533 are close to the E-ring in both models, while Asn722 faces
the D-ring carbonyl oxygen in both models. In addition, the -1
scissile strand thymine base stacks under the D-ring in both models
(Fig. 2 and 3).
In terms of the differences between the two models: 1) In the
Rotated +1 Nucleoside model the A-ring 10-OH makes an
electrostatic interaction with Asn352 (Fig. 2B and 4A), while in the
Intercalated model the A-ring 10-OH H-bonds to Glu356 (Fig. 3B
and 4B); 2) In the Rotated +1 Nucleoside model 10-OH CPT only
stacks with the -1 scissile strand T (Fig. 2), while in the Intercalated
model 10-OH CPT stacks with the -1 and +1 base pairs (Fig. 3).
And while Asn430, Pro431, Leu721, and Lys751 are within 4–
7.7 A ˚ of 10-OH CPT in the Rotated +1 Nucleoside model, those
residues are 1–4 A ˚ further away from 10-OH CPT in the
Intercalated model (data not shown). By determining the
orientation of CPT and derivatives in the Top1 active-site, CPT
derivates could be designed to make additional H-bonds and van
der Waals interactions with one or more of the above residues.
The default Discovery Studio 2.1 definition for H-bonds was used
with H-bonds distances reported here between 3.0–3.1 A ˚
(Accelrys, San Diego, CA).
In order to evaluate the orientation of CPT and derivatives in
the two models, and compare them to the reported in vitro activities
for those same compounds (Figure 1 and Table 1), the interaction
energy scores between CPT and derivatives and the active-sites of
the Rotated +1 Nucleoside model (Fig. 2 and 4A) and the
Intercalated model (Fig. 3 and 4B) were calculated (Fig. 5). For
both models, the CPT interaction energy score (Rotated +1
Nucleoside model: vdW -48.6, E -4.67; Intercalated model: vdW -
69.22, E -5.9) was subtracted from that for 10-OH CPT, 20-deoxy
CPT, and 20-Cl CPT, while the hCPT interaction energy score
Figure 4. Flattened images of two models for Top1 interaction
with dsDNA and 10-OH CPT. A) Flat image of Rotated +1 Nucleoside
model from Fig. 2, H-bonds and electrostatic interactions within 3.6 A ˚
are indicated with dashed lines. B) Flat image of Intercalated model
from Fig. 3, H-bonds and electrostatic interactions within 3.6 A ˚ are
indicated with dashed lines.
doi:10.1371/journal.pone.0024314.g004
Figure 5. Relative interaction energy in kcal/mol between CPT/
hCPT-derivatives and the Top1/dsDNA active-site. The interac-
tion energy scores for the derivatives of CPT and hCPT were subtracted
from the score of the respective parent inhibitor with the resulting
difference values plotted on the graph. The CPT and hCPT interaction
energy scores were set to zero. A negative kcal/mol score indicates that
a derivative bound tighter than the parent inhibitor, while a positive
kcal/mol score indicates that it bound weaker than the parent inhibitor.
A) Interaction energy values for CPT, hCPT and derivatives when bound
in the Rotated +1 Nucleoside model Top1/dsDNA active-site. B)
Interaction energy values for CPT, hCPT and derivatives bound in the
Intercalated model Top1/dsDNA active-site.
doi:10.1371/journal.pone.0024314.g005
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model: vdW -68.63, E -5.54) was subtracted from that for 10,11-
diF hCPT. The resulting difference values for 10-OH CPT, 20-
deoxy CPT, 20-Cl CPT, and 10,11-diF hCPT in the two models
were then graphed to visualize whether an inhibitor bound either
stronger (negative kcal/mol), or weaker (positive kcal/mol), than
either CPT, or hCPT, which were set to zero (Fig. 5). For each of
the following ligands the relative increase/decrease in the van der
Waals (vdW) and electrostatic energy (E) is indicated. It has been
reported that 10-OH CPT and 10,11-diF hCPT were 3.5-fold and
12-fold more potent in vitro than CPT and hCPT, respectively
(Table 1) [15,16]. It was also reported that the racemic 20-deoxy
CPT had 3%, and racemic 20-Cl CPT had 29%, of the inhibition
of CPT (Table 1) [20].
Ligand scores for Rotated +1 Nucleoside model
In the Rotated +1 Nucleoside model, the 10-OH CPT value
was -3.23 kcal/mol (vdW -2.16, E -1.07) stronger than CPT, and
the 10,11-diF hCPT value was -2.03 kcal/mol (vdW -0.16, E -
1.87) (Fig. 5A) stronger than hCPT due to either the A-ring 10-
OH, or 10,11 diF, interacting with Asn352 (Fig. 2B and 4A).
These additional interactions explained why 10-OH CPT and
10,11-diF hCPT were more potent in vitro than CPT and hCPT,
respectively (Table 1) [15,16]. The 20-deoxy CPT value was 1.81
kcal/mol (vdW 1.5, E 0.31) weaker than CPT (Fig. 5A) due to the
loss of the 20-OH interaction with the Top1/dsDNA active-site
(Fig. 5A). This is consistent with the racemic 20-deoxy CPT having
low in vitro activity (Table 1) [20], with the 1.81 kcal/mol value
(vdW 1.5, E 0.31) representing a loss of 6% of the total electrostatic
interaction energy for CPT. Interestingly, the 20-Cl CPT value
was only 0.49 kcal/mol (vdW 0.2, E 0.29) weaker than CPT
(Fig. 5A). This result for 20-Cl CPT is consistent with the lack of a
H-bond between the E-ring 20-Cl and the -1 scissile strand
thymidine carbonyl oxygen (see E-ring 20-OH hydrogen in Fig. 2B
and 4A). However, the 20-Cl CPT is significantly more potent in
vitro than 20-deoxy CPT (Table 1), indicating that the 20-Cl is
contributing to interactions between 20-Cl CPT and Top1/
dsDNA through electrostatic interactions with Arg364 and
Lys532. In the Rotated +1 Nucleoside model the Arg364 side-
chain nitrogens make H-bonds to Asp533 and the -1 non-scissile
strand cytosine and the +1 non-scissile strand adenine, and
electrostatic interactions with the E-ring 20-OH (Fig. 4A). These
interactions by Arg364 would contribute to the stabilization of the
Top1/dsDNA/inhibitor complex (Fig. 2 and 4A). When Arg364
was mutated to His, the mutant Top1 became resistant to CPT
and derivatives [23]. The shorter His side chain can neither make
H-bonds to Asp533 and the -1/+1 non-scissile strand bases, nor
electrostatic interactions with the E-ring 20-OH (data not shown).
These in silico results support the binding orientation for CPT,
hCPT, and derivatives in the Rotated +1 Nucleoside model (Fig. 2).
However, it is important to note that while the 10,11 diF hCPT in
vitro inhibition (Table 1, 12-fold) follows the respective Rotated +1
Nucleoside model difference value of -2.03 kcal/mol (Fig. 5A), the
two values do not correlate in magnitude with the corresponding
values for 10-OH CPT (Table 1, 3.5-fold; and Fig. 5A, -3.23).
Fluorinated compounds have increased hydrophobicity [24],
which in vitro likely results in 10,11-diF hCPT partitioning more
efficiently out of the solvent phase and into the Top1/dsDNA
binding cavity than does 10-OH CPT which is more hydrophilic
due to the A-ring 10-OH. However, the interaction energy
calculations in this study did not take that into account. Consistent
with the reported 12-fold inhibition enhancement for 10,11-diF
hCPT (Table 1), an inhibitor of glycogen phosphorylase, in which
two hydroxyls were replaced with fluorines, was 10-fold more
potent than the non-fluorinated inhibitor [25]. And while the
addition of a hydroxyl to an inhibitor can be used to probe the
active-site of an enzyme for a H-bond donor/acceptor, the
substitution of a hydroxyl on an inhibitor with fluorine can be used
to probe the active-site of an enzyme for the presence of just a H-
bond donor [24,25]. The in vitro data in Table 1 indicates that 10-
OH CPT, 10,11-diF hCPT, and 20-Cl CPT interact with H-bond
donors in the Top1 active-site. The Rotated +1 Nucleoside model
supports this conclusion since Asn352 can donate H-bond/
electrostatic interactions to 10-OH CPT and 10,11-diF hCPT
(Fig. 2B and 4A), and Arg364 and Lys532 which are H-bond
donors can make electrostatic interactions with 20-Cl CPT at
,4A ˚ (data not shown).
Ligand scores for Intercalated model
In the Intercalated model, the 10-OH CPT value of -3.31 kcal/
mol(vdW-2.06,E -1.25) (Fig. 5B)was strongerthan CPTdue to the
10-OH CPT A-ring 10-OH making a H-bond to Glu356 (Fig. 3B
and 4B). In the Staker et al. structure based Top1/suicide-DNA/
topotecan model, the Glu356 side-chain oxygen was 3.8 A ˚ from the
topotecan A-ring 10-OH with a reported B-factor of 48 [18]. The
topotecan A-ring 9-CH2-N-(CH3)2 may have disrupted the
interaction between Glu356 and the adjacent A-ring 10-OH. In
contrast, the 10,11-diF hCPT value of -0.2 kcal/mol (vdW -0.34, E
0.13) was only slightly stronger than hCPT (Fig. 5B), due to an
electrostatic clash between the A-ring 10,11-diF and the Glu356
side-chain oxygens (note positive E value in the above score). These
in silico results for 10,11-diF hCPT appear inconsistent with the
reported in vitro 12-fold increase in inhibition (Table 1) [15]. As
pointed out above, fluorine has been used to probe the active-site of
enzymes for H-bond donors, however, the Glu356 side-chain
oxygens can not donate a H-bond to fluorine. In the Intercalated
model, the 20-deoxy CPT value was 6.03 kcal/mol (vdW 1.91, E
4.12) weaker than CPT with the electrostatic component repre-
senting a loss of 70% of the total electrostatic interaction energy for
CPT (see above, Fig. 5B). The decrease in electrostatics for 20-
deoxy CPT can be explained by the lack of a H-bond between the
20-deoxy CPT E-ring and Asp533; the racemic 20-deoxy CPT had
low in vitro activity (Table 1) [20]. The 20-Cl CPT value of 5.64
kcal/mol (vdW 0.74, E 4.9) was also significantly weaker than CPT
due again to the lack of a H-bond between the 20-Cl CPT E-ring
and the Asp533 side-chain oxygen (see 20-OH group of 10-OH
CPTinFig. 3Band4B). IntheIntercalated model, theCPT20-OH
H-bond to Asp533 is the dominant electrostatic interaction between
the inhibitor and the Top1/dsDNA active-site. However, in the
Intercalated model the 20-Cl makes an electrostatic clash with
Asp533 (see 20-OH of 10-OH CPT in Fig. 3B and 4B). The in silico
results for 10,11-diF hCPT and 20-Cl CPT in the Intercalated
model (Fig. 5B) do not follow the trend for the known in vitro
inhibitionbythese CPT/hCPT derivatives (Table 1).It is important
to note that these in silico results allow for further testing of both
models. FortheIntercalated model tobe biologicallyrelevant (Fig. 3
and 4B) mutation of Top1 Glu356 to Ala should result in a Top1
mutant that could not distinguish between CPT and 10-OH CPT
due to the lack of a H-bond between an Ala356 and the A-ring 10-
OH. In contrast, for the Rotated +1 Nucleoside model, the same
Top1Glu356Alamutantshouldstillbeinhibited,3.5-fold more by
10-OH CPT, than by CPT, because in the Rotated +1 Nucleoside
model the 10-OH CPT A-ring does not interact with Glu356
(Fig. 2B).
For this study, interactions between Top1 residues Glu356 and
Asp533 and CPT derivatives were critical in showing that the
Intercalated model did not support the structure-activity-relation-
ships for chlorinated and fluorinated derivatives of CPT and
Evaluation of Human Topoisomerase I Inhibition
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Intercalated model suggest that the use of suicide-DNA, and high
inhibitor-to-enzyme ratios (,34:1) to generate Top1/suicide-
DNA/inhibitor ternary complexes resulted in non-biologically
relevant binding modes for CPT and derivatives [18,19]. This is
supported by the fact that the Top1/suicide-DNA/topotecan
active-site was found to contain both the lactone (63%) and
carboxylate (37%) forms of topotecan (the same ratio was also
found for topotecan in mother liquor alone) [18]. The Top1/
suicide-DNA/CPT active-site was also found to contain both the
lactone and carboxylate forms of CPT, for which the percentages
were so close they could not be differentiated [19]. In contrast,
Top1 and dsDNA oligonucleotides were reported in vitro to
preferentially stabilize the active lactone form of CPT (97.1%)
versus the inactive carboxylate form (2.9%) [15]. The carboxylate
form of hCPT, which can not reverse to the lactone form, has been
shown to have no detectable inhibitory activity in vitro [15]. It can
be argued that the Staker et al. Top1/suicide-DNA active-site
could not distinguish between active and inactive forms of CPT
and derivatives because the +1 nucleoside was not rotated out of
the helix to open a biologically important inhibitor binding cavity
(Fig. 2) [15]. The Rotated +1 Nucleoside model H-bond/
electrostatic interactions between Arg364 and -1 non-scissile
strand A and +1 non-scissile strand C, Arg488 and +1 scissile
strand G, Lys532 and -1 scissile strand T, and Arg590 and +1
scissile strand G (Fig. 2B and 4A) are consistent with CPT
stabilized Top1/dsDNA covalent-complexes occurring preferen-
tially at sequences containing a -1 scissile strand T/+1 scissile
strand G and followed by other combinations of -1 pyrimidines
and +1 purines/pyrimidines [26].
Here it was also found that the lactone forms of CPT and
derivatives made direct H-bonds to the Top1/dsDNA active-site
in both the Rotated +1 Nucleoside and Intercalated models which
is consistent with: 1) a previous report for a solvated Rotated +1
Nucleoside model [15]; 2) for the X-ray crystallography based
Intercalated model [18]; and 3) molecular dynamic simulations of
the topotecan lactone in the solvated Top1/dsDNA active-site by
Mancini et al. [27].
The probing of the Top1 active-site with CPT derivatives
containingchlorine and fluorine substitutionsforhydroxylsrevealed
that 20-Cl CPT was able to make an electrostatic interaction with
the Top1/dsDNA active-site, and 10,11-diF hCPT interacted with
active-site H-bond donors near the A-ring. Only the binding of
these inhibitors in the Rotated +1 Nucleoside model allows for 20-
Cl CPT to maintain electrostatic interactions with Top1/dsDNA
viaArg364 and Lys532, and forAsn352to interact withfluorines on
10,11-diF hCPT (see 10-OH CPT in Fig. 2B and 4A). Together
these findings further define the orientation of CPT and derivatives
in the Top1 active-site, and allow for the rational design of CPT
derivatives that make additional interactions with the Top1 active-
site residues, including Asn430, Pro431, Leu721, and Lys751. This
approach, in combination with the rational design of CPT
derivatives which avoid cancer cell drug resistance mechanisms
[9,10], has the potential to result in more efficacious CPT
derivatives for the treatment of drug resistant cancers and cancers
that are currently not treated with CPT derivatives.
Methods
Structure based Top1/dsDNA Rotated +1 Nucleoside
model
All Top1/dsDNA and inhibitor modifications, minimizations,
and calculations, were carried out using Discovery Studio 2.0 with
conditions and parameters that were optimized to mimic general
in vitro conditions for direct interactions between ligands and an
enzyme active site (Accelrys, San Diego, CA). 1) In the Redinbo et
al. 1A31.pdb file [11], all waters were deleted, and all 5-iodo-29-
uridines in the DNA were replaced with thymidines. In the Staker
et al. 1K4T.pdb file [18], topotecan (lactone and carboxylate
forms), mercury, PEG, and all waters were deleted. 2) All
incomplete Top1 side-chains were built out in the 1A31.pdb and
1K4T.pdb structures. 3) The 1A31.pdb Top1/suicide-DNA
structure was superimposed with the 1K4T.pdb Top1/suicide-
DNA/topotecan structure using selected atoms in the respective
enzymes and bound dsDNAs. The aligned non-scissile strand
nucleotides 115–122, and scissile strand nucleotides 1–10 in the
1A31.pdb and 1K4T.pdb structures had an RMSD of 0.598 A ˚.
The 1A31.pdb Top1 protein was then deleted. 4) The intercalated
topotecan in the 1K4T.pdb structure displaced the non-scissile
strand nucleotides (101–114) and scissile strand nucleoside 11 and
nucleotides 12–22, and so these portions of the DNA in the
1K4T.pdb structure were deleted leaving the corresponding DNA
from the 1A31.pdb structure. The 1A31.pdb non-scissile strand
bases 115–122 and scissile strand bases 1–10 in the DNA, that
were aligned to the corresponding 1K4T.pdb bases (RMSD,
0.598 A ˚), were also deleted. The 1A31.pdb scissile strand
nucleoside 11 free 59 sulfur (S59) was replaced with the native
oxygen and the thymine base was replaced with a guanine (the
1K4T.pdb scissile strand base 11 is a guanine), and the base
pairing non-scissile strand adenine in the 1A31.pdb DNA was
replaced with a cytosine to allow for proper base pairing to the
scissile strand guanine 11. Note: in the RCSB Protein Data Bank
current ‘‘remediated’’ version of the 1A31.pdb entry, the scissile
strand nucleoside 11 S59 is incorrectly labeled as an O59. 5) The
backbone atoms of nucleotides 114/115 in the remaining non-
scissile strand DNA (nucleotides 101–114 from 1A31.pdb and
115–122 from 1K4T.pdb) were bonded and the entire Top1/
dsDNA covalent-complex was typed with CFF, the bond orders
for the atoms in the tyrosyl-phosphate bond were corrected as
needed, and then minimized with an Implicit Solvent Model using
Implicit Distance-Dependent Dielectrics and no restraints using
first Steepest Descent and then Conjugate Gradient algorithms to
a Final Convergence of 0.1. 6) The +1 nucleoside was rotated,
around the backbone oxygen-phosphorus bond, out of the helix
until the guanine base and deoxyribose 59OH made a network of
H-bonds/electrostatic interactions with Arg488, Asp533, and
Arg590 as previously reported [15]. 7) CPT was docked into the
Top1/dsDNA active-site such that it made the same network of
H-bond/electrostatic interactions with Top1 and dsDNA as
previously reported [15]. CPT was then modified into the
following derivatives: 20-deoxy CPT, 20-Cl CPT, hCPT and
10,11 diF-hCPT. Inhibitors were first typed with CFF and then
the C-ring C15 and C16 atom types in hCPT and derivatives, and
C10 and C11 atoms in CPT and derivatives, were manually
corrected from cpb (bridge carbon biphenyl functional group) to
cp (Sp2 aromatic carbon in either five- or six-member ring).
Inhibitors were then minimized with an Implicit Solvent Model
using Implicit Distance-Dependent Dielectrics and no restraints
using Steepest Descent and then Conjugate Gradient algorithms to
a Final Convergence of 0.1. 8) Next the entire Top1/dsDNA/
inhibitor covalent-complex was typed with CFF (again, inhibitor
C-ring C15 and C16 atom types in hCPT and derivatives, and
C10 and C11 atoms in CPT and derivatives, were corrected from
cpb to cp), and then minimized with an Implicit Solvent Model
(implicit distance-dependent dielectrics, dielectric constant of 3),
Electrostatics spherical cutoff, Nonbond List Radius of 14
(nonbond higher cutoff distance 12, nonbond lower cutoff distance
10), and no restraints using Steepest Descent and then Conjugate
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Energy Change of 0.0, was reached.
Structure based Top1/dsDNA Intercalated model
All modifications and minimizations were carried out using
Discovery Studio 2.0 (Accelrys, San Diego, CA). 1) In the Staker et
al. 1K4T.pdb [18] the topotecan carboxylate, mercury, PEG, and
all waters were deleted. 2) All incomplete Top1 side-chains were
built out and the scissile strand +1 nucleoside 59 sulfur (S59) was
changed to the native oxygen. 3) The topotecan A-ring 9-N(CH3)2
was replaced with a hydrogen to give 10-OH CPT, and then the
A-ring 10-OH was replaced with a hydrogen to give CPT. CPT
was then modified into the following derivatives: 20-deoxy CPT,
20-Cl CPT, hCPT and 9,10 diF-hCPT. Inhibitors were first typed
with CFF and then the C-ring C15 and C16 atom types in hCPT
and derivatives, and C10 and C11 atoms in CPT and derivatives,
were manually corrected from cpb (bridge carbon biphenyl
functional group) to cp (Sp2 aromatic carbon in either five- or
six-member ring) and minimized with an Implicit Solvent Model
using Implicit Distance-Dependent Dielectrics and no restraints
using Steepest Descent and then Conjugate Gradient algorithms to
a Final Convergence of 0.1. 4) Next the entire Top1/dsDNA/
inhibitor covalent complex was typed with CFF (inhibitor C-ring
atom types were corrected from cpb to cp), and then minimized
with an Implicit Solvent Model (implicit distance-dependent
dielectrics, dielectric constant of 3), Electrostatics spherical cutoff,
Nonbond List Radius of 14 (nonbond higher cutoff distance 12,
nonbond lower cutoff distance 10), and no restraints using the
Steepest Descent and then Conjugate Gradient algorithms until
either a RMS Gradient of 0.1, or Energy Change of 0.0, was
reached.
Interaction energy calculations
All calculations were carried out using Discovery Studio 2.0
(Accelrys, San Diego, CA).
The interaction energy scores between inhibitors and Top1/
dsDNA were calculated using an Implicit Solvent Model (implicit
distance-dependent dielectrics, dielectric constant of 3) and a
Nonbond List Radius of 14 (nonbond higher cutoff distance 12,
nonbond lower cutoff distance 10). A dielectric constant of 3 was
used to approximate the direct H-bonds between the ligands and
the Top1/dsDNA active-site residues which excluded the presence
of water (see Results and Discussion) [28,29].
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